News about "Feng Ren"

Insilico Medicine's AI-Discovered CKD Anemia Drug ISM4808 Enters Phase I Trial Under TaiGen Biotechnology Partnership

Insilico Medicine's AI-Discovered CKD Anemia Drug ISM4808 Enters Phase I Trial Under TaiGen Biotechnology Partnership

TaiGen Biotechnology doses first participant in Phase I trial of ISM4808, an AI-designed oral therapy from Insilico Medicine for chronic kidney disease-related anemia.

Feng Ren | 09/03/2026 | By News Bureau 174


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members